IL6 and COVID-19: One clinical trial (ChiCTR2000029765) reported that neutralizing IL-6 with tocilizumab could quickly control the high fever and respiratory symptoms in 21 patients with COVID-19 (11), which revealed the feasibility of anti-inflammation treatment option for COVID-19.